|
Q3 2024
|
68 |
2,037,780 |
RVMD, TYRA, NUVL, 49BA.SG
|
13F-HR
|
11/14/2024 |
000089534524000585 |
|
Q2 2024
|
61 |
1,898,904 |
RVMD, SWTX, CYTK, MRUS
|
13F-HR
|
8/14/2024 |
000089534524000355 |
|
Q1 2024
|
59 |
2,024,741 |
SWTX, CYTK, RVMD, TYRA
|
13F-HR
|
5/15/2024 |
000089534524000182 |
|
Q4 2023
|
52 |
2,006,361 |
MRTX, CYTK, SWTX, RVMD
|
13F-HR
|
2/14/2024 |
000089534524000061 |
|
Q3 2023
|
73 |
1,878,507 |
MRTX, RVMD, 49BA.SG, TYRA
|
13F-HR
|
11/14/2023 |
000089534523000631 |
|
Q2 2023
|
79 |
2,156,238 |
RETA, APLS, RVMD, TYRA
|
13F-HR
|
8/14/2023 |
000089534523000469 |
|
Q1 2023
|
75 |
2,035,630 |
RXDX, RETA, 49BA.SG, SRPT
|
13F-HR
|
5/15/2023 |
000089534523000296 |
|
Q4 2022
|
71 |
1,896,920 |
RXDX, 49BA.SG, CYTK, RVMD
|
13F-HR
|
2/14/2023 |
000089534523000135 |
|
Q3 2022
|
73 |
1,778,081 |
MRTX, CYTK, RXDX, SWTX
|
13F-HR
|
11/14/2022 |
000095012322012323 |
|
Q2 2022
|
76 |
1,578,912 |
MRTX, CYTK, 49BA.SG, RVMD
|
13F-HR
|
8/15/2022 |
000095012322009489 |
|
Q1 2022
|
74 |
1,945,613 |
MRTX, SWTX, ITOS, 49BA.SG
|
13F-HR
|
5/16/2022 |
000095012322006483 |
|
Q4 2021
|
71 |
2,574,770 |
MRTX, XBI, ITOS, 49BA.SG
|
13F-HR
|
2/14/2022 |
000095012322003002 |
|
Q3 2021
|
88 |
2,863,585 |
MRTX, 49BA.SG, SWTX, ITOS
|
13F-HR
|
11/15/2021 |
000095012321015597 |
|
Q2 2021
|
95 |
2,834,340 |
MRTX, 49BA.SG, SWTX, ITOS
|
13F-HR
|
8/16/2021 |
000095012321011427 |
|
Q1 2021
|
85 |
2,948,612 |
MRTX, 49BA.SG, RVMD, SWTX
|
13F-HR
|
5/17/2021 |
000095012321007061 |
|
Q4 2020
|
78 |
3,110,957 |
MRTX, 49BA.SG, SWTX, ITOS
|
13F-HR
|
2/16/2021 |
000095012321002862 |
|
Q3 2020
|
75 |
2,893,710 |
IMMU, 49BA.SG, MRTX, RVMD
|
RESTATEMENT
|
11/17/2020 |
000095012320012232 |
|
Q2 2020
|
65 |
2,274,579 |
IMMU, MRTX, 49BA.SG, ODT
|
13F-HR
|
8/14/2020 |
000095012320009123 |
|
Q1 2020
|
62 |
1,467,229 |
MRTX, IMMU, 49BA.SG, ODT
|
13F-HR
|
5/15/2020 |
000095012320005395 |
|
Q4 2019
|
51 |
1,768,107 |
MRTX, IMMU, 49BA.SG, ODT
|
13F-HR
|
2/14/2020 |
000095012320002532 |
|
Q3 2019
|
49 |
1,379,234 |
ONCE, MRTX, 49BA.SG, IMMU
|
13F-HR
|
11/14/2019 |
000095012319011467 |
|
Q2 2019
|
2 |
19,952 |
ESPERION THERAPEUTICS INC NE calls, IMMUNOMEDICS INC calls
|
NEW HOLDINGS
|
8/15/2019 |
000095012319008514 |
|
Q2 2019
|
35 |
1,143,236 |
MRTX, ODT, 49BA.SG, IMMU
|
13F-HR
|
8/14/2019 |
000095012319008398 |
|
Q1 2019
|
23 |
864,736 |
MRTX, 49BA.SG, IMMU, ODT
|
13F-HR
|
5/15/2019 |
000095012319005411 |
|
Q4 2018
|
24 |
809,378 |
49BA.SG, SLDB, PTCT, WVE
|
13F-HR
|
2/14/2019 |
000095012319002250 |
|
Q3 2018
|
24 |
901,189 |
SLDB, 49BA.SG, PTCT, WVE
|
13F-HR
|
11/14/2018 |
000095012318011923 |
|
Q2 2018
|
26 |
883,149 |
SLDB, 49BA.SG, MRTX, PTCT
|
13F-HR
|
8/14/2018 |
000095012318008984 |
|
Q1 2018
|
33 |
936,874 |
AVXS, 49BA.SG, PTCT, ESPR
|
13F-HR
|
5/15/2018 |
000095012318005733 |
|
Q4 2017
|
26 |
547,127 |
AVXS, ODT, 49BA.SG, ESPR
|
13F-HR
|
2/14/2018 |
000095012318002428 |
|
Q3 2017
|
30 |
439,265 |
AVXS, 49BA.SG, CLVSQ, MGNX
|
13F-HR
|
11/14/2017 |
000095012317010901 |
|
Q2 2017
|
27 |
420,502 |
AVXS, CLVSQ, ESPR, MDCO
|
13F-HR
|
8/14/2017 |
000095012317008000 |
|
Q1 2017
|
31 |
457,649 |
AVXS, CLVSQ, MDCO, ESPR
|
13F-HR
|
5/15/2017 |
000095012317005338 |
|
Q4 2016
|
28 |
258,527 |
AVXS, CLVSQ, MDCO, 49BA.SG
|
13F-HR
|
2/14/2017 |
000095012317002487 |
|
Q3 2016
|
28 |
223,116 |
CLVSQ, MDCO, BPMC, MEDICINES COMPANY calls
|
13F-HR
|
11/14/2016 |
000095012316022431 |
|
Q2 2016
|
23 |
112,781 |
49BA.SG, BPMC, SGEN, INCY
|
13F-HR
|
8/15/2016 |
000095012316020185 |
|
Q1 2016
|
22 |
102,188 |
MRTX, BPMC, 49BA.SG, CPXX
|
13F-HR
|
5/16/2016 |
000095012316017634 |
|
Q4 2015
|
15 |
115,826 |
MRTX, NLTX, BPMC, SGEN
|
13F-HR
|
2/16/2016 |
000095012316015087 |